Enanta Pharmaceuticals (ENTA)
(Real Time Quote from BATS)
$13.53 USD
+0.03 (0.22%)
Updated Apr 23, 2024 11:08 AM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Enanta Pharmaceuticals, Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 79 | 86 | 97 | 122 | 205 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 79 | 86 | 97 | 122 | 205 |
Selling & Adminstrative & Depr. & Amort Expenses | 216 | 210 | 207 | 164 | 168 |
Income After Depreciation & Amortization | -137 | -124 | -110 | -42 | 37 |
Non-Operating Income | 11 | 2 | 2 | 7 | 9 |
Interest Expense | 5 | 0 | 0 | 0 | 0 |
Pretax Income | -131 | -122 | -108 | -35 | 46 |
Income Taxes | 3 | 0 | -29 | 1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -134 | -122 | -79 | -36 | 46 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -134 | -122 | -79 | -36 | 46 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -138 | -120 | -104 | -38 | 36 |
Depreciation & Amortization (Cash Flow) | 0 | 4 | 5 | 4 | -1 |
Income After Depreciation & Amortization | -137 | -124 | -110 | -42 | 37 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 20.97 | 20.60 | 20.17 | 19.94 | 20.97 |
Diluted EPS Before Non-Recurring Items | -6.38 | -5.91 | -3.92 | -0.89 | 2.21 |
Diluted Net EPS (GAAP) | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 |
Fiscal Year end for Enanta Pharmaceuticals, Inc falls in the month of September.
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 18.00 | 18.93 | 18.89 | 17.80 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 18.00 | 18.93 | 18.89 | 17.80 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 52.89 | 49.97 | 55.61 | 57.25 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -34.89 | -31.04 | -36.72 | -39.45 |
Non-Operating Income | NA | 4.30 | 4.66 | 3.87 | 1.84 |
Interest Expense | NA | 3.44 | 3.15 | 2.00 | 0.00 |
Pretax Income | NA | -34.03 | -29.52 | -34.84 | -37.61 |
Income Taxes | NA | -0.62 | -1.41 | 4.22 | 0.04 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -33.41 | -28.11 | -39.07 | -37.66 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -33.41 | -28.11 | -39.07 | -37.66 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 21.09 | 21.06 | 21.05 | 21.04 |
Diluted EPS Before Non-Recurring Items | NA | -1.58 | -1.33 | -1.86 | -1.79 |
Diluted Net EPS (GAAP) | NA | -1.58 | -1.34 | -1.86 | -1.79 |